Let's check how long your stroke medical 'professionals' have been incompetent in not creating protocols for your recovery using this! Someone in that decade should have fired all these people that are not solving stroke!
- growth hormone
(22 posts to March 2013)
Growth hormone as a treatment for post-stroke recovery: a review of
preclinical and clinical evidence
Emmanuelle Zakheim, Daniel Moon, Wesley Tran, Ephrem Gerald and Mohamed Ahmed*
Department of Basic Sciences, College of Medicine, California Northstate University, West Taron
Drive, Elk Grove, CA 95757 USA
* Correspondence: Email: mohamed.ahmed@cnsu.edu.
Abstract:
and cognitive long-term sequelae. Acute reperfusion therapies and prevention strategies are wellestablished, but options to enhance long-term motor and cognitive recovery remain limited. Several pharmacologic adjuncts (selective serotonin reuptake inhibitors (SSRIs), cholinesterase inhibitors,
memantine) have shown inconsistent efficacy or safety, highlighting an unmet need for effective post -
stroke recovery therapies. Growth hormone (GH) has emerged as a candidate adjunctive therapy based on its neurotrophic properties and the discovery of an endogenously activated neural GH axis
following brain injury. This review aims to summarize GH’s proposed mechanisms to promote neurorecovery after a stroke and to synthesize preclinical and clinical evidence supporting its use as
an adjunct to standard post-stroke rehabilitation. A narrative review of preclinical and clinical studies
that examined GH administration following ischemic stroke was conducted, emphasizing functional,
cognitive, and safety outcomes; mechanistic findings connecting GH to neurotrophic signaling,
synaptic plasticity, and cerebrovascular remodeling are also discussed. Preclinical studies
demonstrated that GH administration after a stroke accelerates motor recovery, improves spatial and
associative memory, reduces peri-infarct tissue loss, and increases neurotrophic, synaptic, and
angiogenic markers (BDNF, IGF-1, VEGF). Four human clinical trials, along with the phase I-II
COURAGE trial of GH-secretagogue therapy, reported significant improvements in functional
independence (Korean Modified Barthel Index (K-MBI), motor and cognitive scores (Fugl-Meyer,
Montreal Cognitive Assessment), and reduced neurological deficit (Modified Rankin Scale (mRS),
National Institutes of Health Stroke Scale (NIHSS) in GH-treated patients compared with controls,
without serious adverse events. Preclinical and early clinical evidence supports GH as a promising and
safe adjunct to standard post-stroke rehabilitation, particularly for enhancing motor and cognitive
recovery; however, existing clinical trials are small and varied in design, and larger, multicenter
randomized controlled trials are required to establish optimal dosing, timing, and treatment duration
before GH can be incorporated into standard post-stroke care.
No comments:
Post a Comment